

73SB-83LSB

20 December 1973

Barrett Scoville, M.D.  
Division of Neuropharmacology  
Food and Drug Administration  
5600 Fisher's Lane  
Rockville, Maryland 20852

Dear Barry:

I am enclosing a copy of a letter which I sent Al Gardner in July. In that letter, I was proposing to discuss the use of quantitative electrophysiology to assay the bioavailability of CNS-active drugs.

I think the methods are now sufficiently developed, both in the quantification of EEG and the statistical processing of EEG and behavioral data, to allow more extensive correlations of data collected to assess such questions as the rate at which a drug affects the brain, and comparisons of different dosages and probably different formulations for rate and degree of effect.

I am enclosing a preprint of a report which summarizes our experience to December, 1972; and a reprint published in 1971 on statistical methods used to analyze rate effects with intravenous pentothal.

Should the Division of Neuropharmacology wish to assess these methods, I would be pleased for an opportunity to discuss the experiences and the potentialities in detail.

It was fun flying with you. My best wishes for a happy and healthy 1974.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF/cis  
Encls.